Page last updated: 2024-11-02

pioglitazone and Leukemia, Promyelocytic, Acute

pioglitazone has been researched along with Leukemia, Promyelocytic, Acute in 3 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.

Research Excerpts

ExcerptRelevanceReference
"The indulgent success of arsenic trioxide (ATO) in the induction of complete remission in acute promyelocytic leukemia (APL) patients has accommodated this agent into the therapeutic protocols."7.96Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. ( Bashash, D; Esmaeili, S; Gharehbaghian, A; Hamidpour, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Salari, S, 2020)
"The indulgent success of arsenic trioxide (ATO) in the induction of complete remission in acute promyelocytic leukemia (APL) patients has accommodated this agent into the therapeutic protocols."3.96Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone. ( Bashash, D; Esmaeili, S; Gharehbaghian, A; Hamidpour, M; Pourbagheri-Sigaroodi, A; Safaroghli-Azar, A; Salari, S, 2020)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Esmaeili, S5
Yousefi, AM3
Delshad, M3
Bashash, D5
Safaroghli-Azar, A2
Pourbagheri-Sigaroodi, A2
Salari, S2
Gharehbaghian, A2
Hamidpour, M2

Other Studies

3 other studies available for pioglitazone and Leukemia, Promyelocytic, Acute

ArticleYear
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Synergistic effects of PI3K inhibition and pioglitazone against acute promyelocytic leukemia cells.
    Molecular genetics & genomic medicine, 2023, Volume: 11, Issue:3

    Topics: Apoptosis; Humans; Leukemia, Promyelocytic, Acute; Phosphatidylinositol 3-Kinases; Pioglitazone; Pro

2023
Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
    The international journal of biochemistry & cell biology, 2020, Volume: 122

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Cell Cycle; Cell Line,

2020
Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression.
    Anti-cancer agents in medicinal chemistry, 2021, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Humans; Leuk

2021